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ABSTRACT
NAMI-A, imidazolium trans-imidazoledimet.hylsulfoxidetetrachlororuthenate, is a
ruthenium based compounds capable of inhibitin the growth.of lung metastases of solid
t.urnours in a number of experimental conditions.-The a.lm of this study was to investigate
the potential use ofNAMI-A by the oral rome_to treat lung metastases ofMCa mamm.aD
carcinoma in the CBA mouse. Treatment or mice, carring intramuscular tumour_s .in advagced_ .stage of growth, for 11 consecutive days cause/:l a significant reduction or the
weight oi lung. metastases 9ve.r the.range, of d9ses from. 150 to 6-0.0 .m.g/kg/day. N.o .sign of
toxicity was observed at the histological analysis in the gut epithelium or in the kld.ney
p_arenchyma, and N.AMI-A concentration in tlie kidney was more than 10-fold lower than
alter intraperitone.al treatm_en.ts. NAMI-A is thus active agai.nst metastases also .by the oral
route, suggesting the use orthis way to treat tumour bearing hosts for long periods.
INTRODUCTION
Metastases of solid tumours represent the most-important target for therapy in that
they are the most frequent responsible for the failure of cancer therapy. Metastases are
always scattered, often in more than one vital organ, and ate not erasable by conventional
surgery and/or radiotherapy. On the other hand, cytotoxic cancer chemotherapy fails
against solid tumour metastases in that, among all, metastases differ from the primary
tumours of origin because of poor sensitivi to conventional drugs [1-3]. Drugs active
against metastases are therefore strongly desired. These drugs should show the capacity of
inhibitin metastasis growth (i.e. the growth of metastases already formed), besides
metastass formation (i.e. the steps that bring turnout cells to form distant metastases) [4].
It is thus important to get the so-called antimetastasis agents rather than the mostly known
antimetastatc drugs, provided that in human beings the most probable drug treatment is for
already established metastases. In recent years, we accumulated a strong evidence for the
effects of some ruthenium complexes on solid tumour metastases in mice bearing
experimental tumours [5-7]. Of these complexes, the one called NAMI-A (imidazolium
trans-imidazoletedimethylsulfoxidetrachlororuthenate) showed adherence to the above
characteristics: it is active aainst spontaneous metastases of solid turnouts also when drug
treatment occurs in mice wtth advanced turnouts, i.e. at a time at which metastases are
already settled in the lungs [5,8]. Moreover, NAMI-A appears to control metastasis growth
by a mechanism unrelated to direct cell cytotoxicity, typical of conventional chemotherapy
agents, still showing effects similar or even superior to those of a drug ofwide clinical use
such as cisplatin [7,9-11]. More recently, NAMI-A, though undergoing a series of
molecular metabolisms in aqueous solutions, was shown capable of maintaining its
antimetastatic activity in a broad range of experimental conditions, thus suggesting the
possibility ofhandling its clinical management in a rather flexible way [12].
The aim of the present investigation was therefore that of examining the effects of
NAMI-A given by the oral route to mice bearing the solid metastasising tumour MCa
mammary carcinoma. The efficacy of NAMI-A by this route of administration should
facilitate the treatment oftumour bearing hosts to cover a relatively long period of time, as
probably required for the metastatic pathology. In fact, provided that NAMI-A has
repeatedly shown efficacy against metastases wih a mechanism involving the alteration of
the cancer cells with host cells/tissues [13], the reduction of metastases fill their complete
removal might require a long exposure of the tumour cells to the drug. In this respect, the
oral route may meet this requirement, particularly if a better compliance is also proved by
the host. This study therefore examines the effects of NAMI-A on lung metastasis
formation in the light of the effects of the complex on primary tumour, on gut epithelium
and kidney and on i:uthenium uptake by these tissues.Gianni Sava et al. Pharmacological Effects ofthe Ruthenium Complex Nami-A
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MATERIALS AND METHODS
Compounds and treatment. NAMI-A was 13rep.ared according to a patented procedure
(Mestroni et al., 1998). The drug was adminisfer&l orally admixed throug.hout the powered
food. Animal treatment waspeforrned on days 10-21 after ttunour implantation. All the
animals were pre-copditio.nedto p.owdered food for 2-weeks before the e.xperiment. Drug
concentration was selected to provide 100, 150, 200, 300 and 600 mg/kg/die on the basis o-f
an a.yerage daily food consumption of 5.00.1. g per mo.use, .terr.ine.d in the _pr.e-
conditiomng period. Food consumption remained constant throughout the duration otthe
experiment n either Controls or in lhe group receiving NAMI-A.
Tumour line. MCa mamma, carcinoma cells (grown in CBA mice) were used for in vivo
testing. CBA .mice were olbtained from a locally established breeding colony grown
according to the standard procedures for inbred s(rains. The tumour lzrat p.rocedure for
MCa mammary carcinoma were the same as those already described in letai[ [14]. Briefl.y,
tumour cells of a single cell suspension were prep.arec[ from mincing with scissors thf
primary turnout masses obtained from. donors similarly, imolanted 2-weeks before. 10
single viable tumour cells were injected i.m. into the left hind’leg calves ofmice in groups
of g-10 animals.
Animal studies were carried out according to the guidelines in force in Italy (DDL
116 of 21/2/1992) and in comoliance to the Guide for the Care and Use of Laboratory
_Animals, Department of Health _and Human Services Publication No. (NIH)86-23,
13ethesda, MD, National Institutes of Health, 1985.
t.u.mour..growth and lung m_etastasis, evalu.ation. Pr’.ma.ary turnout gr.owth was
etermined by callper measureme,s oftwo orthogonal axes andthe tumour volume w.as calculate.d by the f6rmula: (:r/.6)xa xb, wherein a is fhe_shorter and b is the longer axis; the
tumq, density, was .assumed to_b.e equal to one.. Lu0.g .meta.st.a.ses w_er.e counte.d .by
caretully examining the surface or the lungs, immediately alter killing or the animals by.
cervicaldislocation. Lungs were dissected into the five lobes, washed with PBS an;:l
ex.ained under a low 19ower microscope ecluipped with a .calibrated grid. The weight o.f
e.acla metastasis.was .c.arqula.ted by. applying.the sate.e foma.ula_as, t0r primary tumours and
the sum or each individual weight gave the total weight or the metastatic tumour per
animal.
Histololieal analysis. Sections for light microscopy were prepared from paraffin
embedd’6d kidneys and gut (from ileum) sections, which were removed, washed in water
and. fixed in 10% formal.ine and processed according to the standard procedure for
inclusion and followi.ng rehydration (xylene, alcohol, vater), with sections cut at 6 tm. tsections were_stained ith Cajal-Gallego mounted in Canada Balsam and were observed
with a Leitz-Orthoplan microscop.e. Examinations were made on three different slides,
each containing three slices for each sample.
AAS of rutlienium. Ruthenium was measured in trip.licate by atomic absorption
spectroscopy, using a Varian SpectrAA-300 instrumental.ion supolied with a graphite
Furnace mol GT/(-96, an autosa,pler mod PSD-96, and a sp.ecffic ruthenium emission
lamp (Hollow cathod 1_agap Varian P/N 56-101447-00). Rdthenium was measured in
samples of 1Q 1_at 349.9m with an ato_misingtemperature of 2,500C, .u.s.ing argon as
purge gas at the flow rate of 3.0 1/min. Before dmly. analysis, a five point calitration curve
_w_as performed by Ruthenium Custom-Grade Stanlard 998 txg/ml in 3.3% HC1 (Inorganic
_Ventures Inc., Lakewood, NJ, USA).
Statistical analy_sis. Experimental raw data were submitted to computer-assisted statistical
analysis using ANOVA analysis ofvariance and Tukey-Kramer post-test.
RESULTS AND DISCUSSION
The effects ofNAMI-A, given orally to mice bearing MCamamm carcinoma in
advanced stage of growth, on lung metastasis formation are shown in Figure 1. On
0 metastasis number, NAMI-A caused the reduction to about 55-60A ofuntreatedcontrols at
any dose tested from 150 to 600 mg/kg/day; the submission ofthese results to the one-way
analysis of variance showed a signi-ficant reduction at the doses of 150 and 600 mg/kg/day,
indicating that the rather wide variation observed in the treated groups rediced the
statistical significance at the other doses.Metal Based Drugs Vol. 8, Nr. 1, 2001
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Figure 1. Effects ofthe oral treatment with NAMI-A on the growth of lung metastasis.
Groups of 8 CBA female mice, implanted i.m. with 106 MCa mammary carcinoma
cells on day 0, were given daily NAMI-A, at the above daily doses, orally on days 10-21.
Mice were killed and lung metastases counted on day 23. Each value is the mean+/-S.E.
obtained in each group (---: metastasis number,: metastasis weight). Data were obtained
in four separate experiments, each performed with appropriate untreated controls fed with
the same type of food without NAMI-A; in detail, the results of the doses of 100, 200, 300
and 400 mg/kg were repeated twice in two repeated experiments. The representative values
obtained in control mice are: 28.4+/-3.0- 37.4+/-7.2 (metastasis number), and 97.2+/-17.6
128+22.3 (metastasis weight). *p<0.05, **p<0.01, ***p<0.001 vs the controls of the
respective experiments.
Conversely, on metastasis weight NAMI-A resulted active with any dose used from 150
mg/kg/d.ay onward (Figure 1), and the reduction was around 40% ofuntreated controls. For
comparison, the i.p. treatment at different doses and schedules showed a similar trend (i.e.
marked inhibition of metastasis weight). However, the extent of metastasis reduction was
generally superior being around 10-20% ofuntreated controls [5,8].
The effects on pdm_azy tumour growth (similarly to the i.p. treatment and
independently of the dose-level used) was much less evident and statistically not
significant (data not reported). Similarly, none of the doses used for the oral treatment
caused host toxicity, as determined by the variation of body weight gain between the start
and the end oftreatment in comparison to untreated controls.Gianni Sara et al. Pharmacological Effects ofthe Ruthenium Complex Nami-A
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Figure 2. Effects of the oral treatment with NAMI-A on the body weight of animals.
Body w.e!ght variation between the beginning and the end of treatment in the groups
of mice receiving NAMI-A was expressed as % versus untreated controls. None of the
report
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Figure 3. Ruthenium concentration in the kidney ofmice of Figure 1.
ed differences can be considered statistically significant.Metal BasedDrugs VoL 8, Nr. 1, 2001
The measurement of ruthenium in the kidney of mice treated orally with NAMI-A
shows that the concentration of the metal (referred as NAMI-A) increases proportionally to
the daily dose used (Figure 3). Indeed, the amount ofNAMI-A found in the kidney ofthese
animals was markedly lower than after i.p. administration. By comparison we may report
the data obtained with the dose of 35 mg&g/day given daily for 6 consecutive days. In this
case, the amount ofNAMI-A found in the kidney was approximately 10 to 20-f01d greater
than that reported in Figure 3, at the higher dose of 600 mg/kg/day for 11 consecutive days.
The kidneys of mice of Figure 1 were processed for flameless atomic absorption
spectroscopy analysis of ruthenium content. Each value is the mean+S.E, obtained from at
least three separate samples obtained from three different mice per group.
Figure 4. Histological appearance of mmour parenchyma of mice treated with 200
mg/kg/day NAMI-A for 11 consecutive days.
C: connective tissue; T: mmour mass; arrows show the external border ofthe tumour mass.
The oral treatment with NAMI-A induces a marked modification of the appearance of
tumour parenchyma, particularly at the external border which appears more regular at the
interface with the surrounding tissue and with an increased density of connective tissue.
Apparently, mmour cells do not appear to be modified by the treatment with NAMI-A and
their density is similar to that of the control samples. At a greater magnification it is
possible to appreciate better the changes at the border of the primary mmour mass on
Which severalinflammatory cells are distinguishable. These alteration are perfectly similar
to those observed following i.p. treatment of this turnout [5]. A detailed examination ofthe
cells of Figure 5 shows the presence of infiltrating leukocytes, particularly PMNs and
lymphocytes (shown by arrows), already evidenced following the i.p. treatment in primary
tumour masses ofboth i.m. and s.c. growing tumours [13].
Figure 5. Histological appearance of tumour
parenchyma ofmice treated with NAMI-A.
Higher magnification (sector C) of Figure 4.
Collagen fibres are coloured in grey-blue
and appear scattered among the mmour cells
in the third top of the figure. Arrows show
some infiltrating leukocytes (Top left: PMN;
middle: lymphocyte; right down: monocyte)Gianni Sava et al. Pharmacological Effects ofthe Ruthenium Complex Nami-A
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The examination of gut epithelium and kidney parenchyma, of mice treated orally with
NAMI-A, by histological staining and light microscopy analysis, showed no appreciable
alteration ofthe architecture ofthe tissues examined (Figure 6). Gut epithelium was regular
and the only change consisted of an increased density of connective tissue on the basal
membrane over untreated controls. Kidney tubules and glomeruli appear regular with cells
well defined and no presence of cell suffering, dilation of tubules or swelling of the
extracellular matrix.
Figure 6. Histological appearance ofkidney parenchyma (top) and gut epithelium (bottom)
of control mice (left) andof mice treated Wiih NAMI-A (right). Slices were prepared from
mice of the experiments of Figure 1 and represent a picture present independently of the
dose of NAMi-A used and ofthe experimem chosen. The evaluation of the histological
changes induced by NAMI-A was made in a single blind experiment with at least three
different glasses, each mounted with three independent slices, per animal. Arrows highlight
the increased thickness ofcollagen fibres under basal membrane.
CONCLUSION
Among the most important promising ruthenium complexes appeared in the literature
[15-16], those with sulf0xide ligands still continue to show the better pharmacological
properties against solid tumour metastases.
NAMI-A proved to be active against solid tumour metastases also when given by the
oral route over a 10 day period to mice with advanced MCa mammary carcinoma.
Although the overall effect-is slightly less pronounced than that obtained following i.p.
treatment, it must be stressed that by this route of administration the kidney concentration
of the compound is markedly lower and no histological toxicity is evidenced. The lack of
toxicity at the gut level and on kidneys suggest the possibility to use NAMI-A by this route
also for periods longer than that usedin tfi6 present study. Provided that to keep metasases
under full control by non cytotoxic drugs such as NAMI-A, they should be treated for long
periods, these data suggest the feasibility of this treatment and its effectiveness.Metal BasedDrugs VoL 8, Nr. 1, 2001
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